Tandem Diabetes Care, Inc. - Common Stock (TNDM)
15.20
+0.00 (0.00%)
NASDAQ · Last Trade: Jul 16th, 6:26 AM EDT
The past year hasn't been kind to the stocks featured in this article.
Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
Via StockStory · July 14, 2025
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies.
The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions.
Via StockStory · July 11, 2025
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
Via StockStory · July 11, 2025
Shares of diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
fell 3.5% in the morning session after a Citi analyst downgraded the stock. Citi analyst Joanna Wuensch downgraded Tandem Diabetes Care from a "Neutral" to a "Sell" rating and significantly cut the price target on the shares to $24 from $35. This move signals rising concerns about the company's future performance and competitive position in the diabetes technology market.
Via StockStory · July 9, 2025
Via Benzinga · July 9, 2025
A proposal would cut Medicare reimbursements for some medical devices using a competitive bidding process.
Via Investor's Business Daily · July 1, 2025
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Via StockStory · June 23, 2025
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold.
Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.
Via StockStory · June 18, 2025
The agreement is to develop and commercialize integrated diabetes solutions that combine Abbott's future dual glucose-ketone sensor with San Diego, California- based Tandem's innovative insulin delivery systems.
Via Stocktwits · June 10, 2025

Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral.
Via Benzinga · June 2, 2025
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Tandem Diabetes (NASDAQ:TNDM) and its peers.
Via StockStory · May 26, 2025
A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could worsen the already wide US fiscal deficit. A poor auction for 20-year U.S. Treasury bonds further raised concerns, as weak demand implies investors are becoming more cautious about holding long-dated U.S. debt.
Via StockStory · May 21, 2025
The stocks featured in this article are seeing some big returns.
Over the past month, they’ve outpaced the market due to new product launches, positive news, or even a dedicated social media following.
Via StockStory · May 16, 2025
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) announced better-than-expected revenue in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects the full year’s revenue to be around $1 billion, close to analysts’ estimates. Its non-GAAP loss of $0.67 per share was 9.5% below analysts’ consensus estimates.
Via StockStory · May 14, 2025
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
Via StockStory · May 12, 2025
Via Benzinga · May 1, 2025
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects the full year’s revenue to be around $1 billion, close to analysts’ estimates. Its GAAP loss of $1.97 per share was significantly below analysts’ consensus estimates.
Via StockStory · April 30, 2025
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects the full year’s revenue to be around $1 billion, close to analysts’ estimates. Its GAAP loss of $1.97 per share was significantly below analysts’ consensus estimates.
Via StockStory · April 30, 2025
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM)
will be reporting results tomorrow after the bell. Here’s what you need to know.
Via StockStory · April 29, 2025
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains.
This unpredictability can shake out even the most experienced investors.
Via StockStory · April 22, 2025
Let’s dig into the relative performance of Tandem Diabetes (NASDAQ:TNDM) and its peers as we unravel the now-completed Q4 healthcare technology earnings season.
Via StockStory · April 15, 2025
Via The Motley Fool · April 12, 2025